JAK1 and temporal arteritis: In a Phase 3 trial of upadacitinib (a JAK1-selective inhibitor) in GCA, sustained remission rates at 52 weeks were significantly higher (15 mg (46%) vs. placebo (29%)), with additional steroid-sparing effects [103].